Syndax Pharmaceuticals Inc (NASDAQ:SNDX) – Equities researchers at Oppenheimer raised their FY2019 EPS estimates for shares of Syndax Pharmaceuticals in a research note issued to investors on Monday, October 29th. Oppenheimer analyst H. Singh now forecasts that the company will earn ($3.99) per share for the year, up from their previous forecast of ($4.63). Oppenheimer also issued estimates for Syndax Pharmaceuticals’ FY2020 earnings at ($4.02) EPS, FY2021 earnings at ($3.97) EPS and FY2022 earnings at $0.37 EPS.
Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its earnings results on Tuesday, August 7th. The company reported ($0.74) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.87) by $0.13. The firm had revenue of $0.38 million for the quarter, compared to analyst estimates of $0.38 million. Syndax Pharmaceuticals had a negative return on equity of 80.35% and a negative net margin of 3,190.51%.
Shares of NASDAQ SNDX opened at $4.77 on Wednesday. The company has a market capitalization of $117.01 million, a P/E ratio of -1.64 and a beta of 1.28. Syndax Pharmaceuticals has a 52 week low of $4.36 and a 52 week high of $15.20.
A number of institutional investors have recently added to or reduced their stakes in SNDX. BlackRock Inc. boosted its position in Syndax Pharmaceuticals by 11.0% in the 1st quarter. BlackRock Inc. now owns 1,276,671 shares of the company’s stock worth $18,168,000 after purchasing an additional 126,941 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Syndax Pharmaceuticals by 77.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 397,579 shares of the company’s stock worth $5,658,000 after purchasing an additional 173,821 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in Syndax Pharmaceuticals by 266.9% in the 1st quarter. The Manufacturers Life Insurance Company now owns 10,566 shares of the company’s stock worth $151,000 after purchasing an additional 7,686 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. raised its stake in shares of Syndax Pharmaceuticals by 433.3% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 70,140 shares of the company’s stock worth $492,000 after buying an additional 56,988 shares during the period. Finally, Aviva PLC acquired a new position in shares of Syndax Pharmaceuticals during the 2nd quarter worth approximately $423,000. Institutional investors and hedge funds own 64.29% of the company’s stock.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial.
Featured Story: How to Invest in a Bull Market
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.